Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2025.Sep.03

News

OBI Pharma and AP Biosciences Sign Technology Collaboration Agreement to Develop Next-Generation ADC

2025.Sep.01

News

OBI Pharma, Inc. Announces Board Resolution for Capital Reduction to Offset Accumulated Losses and Holds Material Information Press Conference

2025.Aug.31

News

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

Read More

2025.Sep.01

Announcement

Press Conference on Material Information Regarding the Board Resolution for Capital Reduction to Offset Accumulated Losses

2025.Sep.01

Announcement

The Company’s Board of Directors resolved to conduct a capital reduction to offset accumulated losses.

2025.Sep.01

Announcement

The Company’s Board of Directors resolved to convene the 2025 first extraordinary general shareholders’ meeting

2024 Annual Report

Learn how we created value in 2024 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2025 Investors' Meeting - Innovation in Action

Download PDF

Read More

2025 First Extraordinary General Shareholders’ Meeting

  • 2025.Oct.20 at 09:00 AM
  • Taipei Bioinnovation Park 1F Conference Room

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact